A harm biomarker suggests a substance or methodology that is normal for the proximity of illness in the body. A biomarker may be an iota produced by a tumor or a specific response of the body to the proximity of sickness. Inherited, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for sickness investigation, surmise, and the investigation of ailment transmission. Ideally, such biomarkers can be tried in non-rudely assembled biofluids like blood or serum. The worldwide malignant growth biomarkers market is represented USD 10.31 billion of every 2016 and is required to develop at a CAGR of 12.2% to USD 20.48 billion by 2022 during the figure time frame.
ALSO READ Oncology Pancreatic Cancer Breast Cancer Oral and Oropharyngeal Cancer Eye Cancer Uterine Cancer Lung Cancer Skin Cancer Kidney Cancer Bladder Cancer Prostate Cancer Colorectal Cancer Anal Cancer Cervical Cancer Bone Cancer Liver Cancer Stomach Cancer Blood Cancer Brain Cancer Gastrointestinal Cancer Ovarian and Testicular Cancer Cardio-Oncology Biochemistry of Cancer Cancer Biomarkers Cancer and HIV Cancer Research and Cancer Vaccines Cancer Genetics Cancer Trends and Opportunities Nanotechnology Nanomedicine in Cancer Treatment Radiology and Imaging in Cancer Artificial Intelligence AI and its Scope in Cancer Therapy Treatment of Cancer Nutrition and Oncology
Oncology Conferences Oncology Conferences 2020 Kidney Cancer Conferences Occular Oncology Conferences Pathology Conferences Nuclear Medicine Conferences Surgical Oncology Conferences Oncologists Conferences 2020 Cancer Science Conferences 2020 Middle-East Cancer Therapy Conferences 2020 Biomarkers Conferences Endometrial Cancer Conferences Cancer Science Conferences Translational Oncology Conferences Molecular Oncology Conferences